Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
|Articles|May 1, 2015
Jasmine Martin Discusses Oral Adherence
Author(s)Jasmine Martin
Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.
Advertisement
Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.
“If patients aren’t taking their drugs, then how do we know that the outcomes will be [the same as] what the clinical trial [outcomes] were?” Martin asks.
Advertisement
Related to this article
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
A breast surgeon explains why patients should raise lymphedema with their care team at the start of treatment, and how early detection can make it reversible.
A woman with stage 4 pancreatic cancer shares how a once-daily RAS inhibitor changed her energy, routine and time with family.
Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
Advertisement
Advertisement
Trending on CURE
1
Medicare Part D 2027: What a $2,400 Cap Means for Cancer Drugs
2
FDA Approves Imfinzi Plus Padcev for Some With Muscle-Invasive Bladder Cancer
3
5 Lung Cancer Survival Numbers Patients Should Know in 2026
4
Tattoos and Lymphoma Risk: A Breast Cancer Survivor's Questions
5